POM: Prescription only medicine
This information is intended for use by health professionals
PosologyPanitaz should be administered every 7th day.
Patients aged 18 years and over:The lowest Panitaz dose (Panitaz 5 micrograms/h transdermal patch) should be used as the initial dose. Consideration should be given to the previous opioid history of the patient (see section 4.5) as well as to the current general condition and medical status of the patient.
Titration:During initiation and titration with Panitaz, patients should use the usual recommended doses of short-acting supplemental analgesics (see section 4.5) as needed until analgesic efficacy with Panitaz is attained.The dose should not be increased before 3 days, when the maximum effect of a given dose is established. Subsequent dosage increases may then be titrated based on the need for supplemental pain relief and the patient's analgesic response to the patch.To increase the dose, a larger patch should replace the patch that is currently being worn, or a combination of patches should be applied in different places to achieve the desired dose. It is recommended that no more than two patches are applied at the same time, regardless of the patch strength. A new patch should not be applied to the same skin site for the subsequent 3-4 weeks (see section 5.2). Patients should be carefully and regularly monitored to assess the optimum dose and duration of treatment.
Conversion from opioids:Panitaz can be used as an alternative to treatment with other opioids. Such patients should be started on the lowest available dose (Panitaz 5 micrograms/h transdermal patch) and continue taking short-acting supplemental analgesics (see section 4.5) during titration, as required.
Patients under 18 years of age:As Panitaz has not been studied in patients under 18 years of age the use of Panitaz in patients below this age is not recommended.
Elderly:No dosage adjustment of Panitaz is required in elderly patients.
Renal impairment:No special dose adjustment of Panitaz is necessary in patients with renal impairment.
Hepatic impairment:Buprenorphine is metabolised in the liver. The intensity and duration of its action may be affected in patients with impaired liver function. Therefore patients with hepatic insufficiency should be carefully monitored during treatment with Panitaz.Patients with severe hepatic impairment may accumulate buprenorphine during treatment. Consideration of alternate therapy should be considered, and Panitaz should be used with caution, if at all, in such patients.
Method of administrationPanitaz is for transdermal use.
Patch application:Panitaz should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest, but not to any parts of the skin with large scars. Panitaz should be applied to a relatively hairless or nearly hairless skin site. If none are available, the hair at the site should be cut with scissors, not shaven.If the application site must be cleaned, it should be done with clean water only. Soaps, alcohol, oils, lotions or abrasive devices must not be used. The skin must be dry before the patch is applied. Panitaz should be applied immediately after removal from the sealed sachet. Following removal of the protective layer, the transdermal patch should be pressed firmly in place with the palm of the hand for approximately 30 seconds, making sure the contact is complete, especially around the edges. If the edges of the patch begin to peel off, the edges may be taped down with suitable skin tape. The patch should be worn continuously for 7 days.Bathing, showering, or swimming should not affect the patch. If a patch falls off, a new one should be applied.
Duration of administration:Panitaz should under no circumstances be administered for longer than absolutely necessary. If long-term pain treatment with Panitaz is necessary in view of the nature and severity of the illness, then careful and regular monitoring should be carried out (if necessary with breaks in treatment) to establish whether and to what extent further treatment is necessary.
Discontinuation:After removal of the patch, buprenorphine serum concentrations decrease gradually and thus the analgesic effect is maintained for a certain amount of time. This should be considered when therapy with Panitaz is to be followed by other opioids. As a general rule, a subsequent opioid should not be administered within 24 hours after removal of the patch. At present, only limited information is available on the starting dose of other opioids administered after discontinuation of the transdermal patch (see section 4.5).
Patients with fever or exposed to external heat:While wearing the patch, patients should be advised to avoid exposing the application site to external heat sources, such as heating pads, electric blankets, heat lamps, sauna, hot tubs, and heated water beds, etc., as an increase in absorption of buprenorphine may occur. When treating febrile patients, one should be aware that fever may also increase absorption resulting in increased plasma concentrations of buprenorphine and thereby increased risk of opioid reactions.
Effect of other active substances on the pharmacokinetics of buprenorphine:Buprenorphine is primarily metabolised by glucuronidation and to a lesser extent (about 30%) by CYP3A4.Concomitant treatment with CYP3A4 inhibitors may lead to elevated plasma concentrations with intensified efficacy of buprenorphine.A drug interaction study with the CYP3A4 inhibitor ketoconazole did not produce clinically relevant increases in mean maximum (Cmax) or total (AUC) buprenorphine exposure following buprenorphine with ketoconazole as compared to buprenorphine alone.The interaction between buprenorphine and CYP3A4 enzyme inducers has not been studied.Co-administration of buprenorphine and enzyme inducers (e.g. phenobarbital, carbamazepine, phenytoin and rifampicin) could lead to increased clearance which might result in reduced efficacy.Reductions in hepatic blood flow induced by some general anaesthetics (e.g. halothane) and other medicinal products may result in a decreased rate of hepatic elimination of buprenorphine.
Pharmacodynamic interactions:Panitaz should be used cautiously with:Benzodiazepines: This combination can potentiate respiratory depression of central origin, with risk of death in case of overdose (see section 4.4).Other central nervous system depressants: other opioid derivatives (analgesics and antitussives containing e.g. morphine, dextropropoxyphene, codeine, dextromethorphan or noscapine). Certain antidepressants, sedative H1-receptor antagonists, alcohol, anxiolytics, neuroleptics, clonidine and related substances. These combinations increase the CNS depressant activity.Buprenorphine is a partial mu-receptor agonist but it is described to function as a pure mu receptor agonist at typical analgesic doses. These doses produce buprenorphine exposures comparable to or greater than those produced by buprenorphine 5, 10, and 20 micrograms/h transdermal patches. In buprenorphine clinical studies, where subjects receiving full mu agonist opioids (up to 90 mg oral morphine or oral morphine equivalents per day) were transferred to buprenorphine, there were no reports of abstinence syndrome or opioid withdrawal during conversion from entry opioid to buprenorphine (see section 4.4).
PregnancyThere are no data from the use of buprenorphine in pregnant women. Studies in animals have shown reproductive toxicity (see Section 5.3). The potential risk for humans is unknown.Towards the end of pregnancy high doses of buprenorphine may induce respiratory depression in the neonate even after a short period of administration. Long-term administration of buprenorphine during the last three months of pregnancy may cause a withdrawal syndrome in the neonate.Therefore Panitaz should not be used during pregnancy and in women of childbearing potential who are not using effective contraception.
BreastfeedingStudies in rats have shown that buprenorphine may inhibit lactation. Excretion of buprenorphine into the milk in rats has been observed. Data on excretion into human milk are not available. Therefore the use of Panitaz during lactation should be avoided.
|Immune system disorders|
|Very rare||anaphylactic reaction, anaphylactoid reactions|
|Metabolism and nutrition disorders|
|Common||confusion, depression, insomnia, nervousness|
|Uncommon||sleep disorder, restlessness, agitation, depersonalisation, euphoric mood, affect lability, anxiety, hallucinations, nightmares|
|Rare||psychotic disorders, decreased libido|
|Very rare||drug dependence, mood swings|
|Nervous system disorders|
|Very common||headache, dizziness, somnolence|
|Uncommon||sedation, dysgeusia, dysarthria, hypoaesthesia, memory impairment, migraine, syncope, tremor, abnormal co-ordination, disturbance in attention|
|Rare||balance disorder, speech disorder|
|Very rare||involuntary muscle contractions|
|Uncommon||dry eye, blurred vision|
|Rare||visual disturbance, eyelid oedema, miosis|
|Ear and labyrinth disorders|
|Very rare||ear pain|
|Uncommon||angina pectoris, palpitations, tachycardia|
|Uncommon||hypotension, circulatory collapse, hypertension, flushing|
|Respiratory, thoracic and mediastinal disorders|
|Uncommon||asthma aggravated, cough, hypoxia, rhinitis, wheezing, hyperventilation, hiccups|
|Rare||respiratory depression, respiratory failure|
|Very common||constipation, dry mouth, nausea, vomiting|
|Common||abdominal pain, diarrhoea, dyspepsia|
|Rare||diverticulitis, dysphagia, ileus|
|Skin and subcutaneous tissue disorders|
|Very common||pruritus, erythema|
|Common||rash, sweating, exanthema|
|Uncommon||dry skin, face oedema, urticaria|
|Very rare||pustules, vesicles|
|Musculoskeletal and connective tissue disorders|
|Uncommon||muscle cramp, myalgia, muscular weakness, muscle spasms|
|Renal and urinary disorders|
|Uncommon||urinary retention, micturition disorders|
|Reproductive system and breast disorders|
|Rare||erectile dysfunction, sexual dysfunction|
|General disorders and administration site conditions|
|Very common||application site pruritus, application site reaction|
|Common||tiredness, asthenia, pain, peripheral oedema, application site erythema, application site rash, chest pain|
|Uncommon||fatigue, influenza-like illness, pyrexia, rigors, malaise, oedema, drug withdrawal syndrome|
|Rare||application site inflammation*|
|Uncommon||alanine aminotransferase increased, weight decreased|
|Injury, poisoning and procedural complications|
|Uncommon||accidental injury, fall|
Reporting of suspected adverse reactionsReporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard.
Absorption:Following buprenorphine application, buprenorphine diffuses from the patch through the skin. In clinical pharmacology studies, the median time for buprenorphine 10 μg/h to deliver detectable buprenorphine concentrations (25 picograms/ml) was approximately 17 hours. Analysis of residual buprenorphine in patches after 7-day use shows 15% of the original load delivered. A study of bioavailability, relative to intravenous administration, confirms that this amount is systemically absorbed. Buprenorphine concentrations remain relatively constant during the 7-day patch application.
Application site:A study in healthy subjects demonstrated that the pharmacokinetic profile of buprenorphine delivered by buprenorphine is similar when applied to upper outer arm, upper chest, upper back or the side of the chest (midaxillary line, 5th intercostal space). The absorption varies to some extent depending on the application site and the exposure is at the most approximately 26 % higher when applied to the upper back compared to the side of the chest.In a study of healthy subjects receiving buprenorphine repeatedly to the same site, an almost doubled exposure was seen with a 14 day rest period. For this reason, rotation of application sites is recommended, and a new patch should not be applied to the same skin site for 3-4 weeks.In a study of healthy subjects, application of a heating pad directly on the transdermal patch caused a transient 26 - 55% increase in blood concentrations of buprenorphine. Concentrations returned to normal within 5 hours after the heat was removed. For this reason, applying direct heat sources such as hot water bottles, heat pads or electric blankets directly to the patch is not recommended. A heating pad applied to a buprenorphine site immediately after patch removal did not alter absorption from the skin depot.
Distribution:Buprenorphine is approximately 96% bound to plasma proteins.Studies of intravenous buprenorphine have shown a large volume of distribution, implying extensive distribution of buprenorphine. In a study of intravenous buprenorphine in healthy subjects, the volume of distribution at steady state was 430 l, reflecting the large volume of distribution and lipophilicity of the active substance.Following intravenous administration, buprenorphine and its metabolites are secreted into bile, and within several minutes, distributed into the cerebrospinal fluid. Buprenorphine concentrations in the cerebrospinal fluid appear to be approximately 15% to 25% of concurrent plasma concentrations.
Biotransformation and elimination:Buprenorphine metabolism in the skin following buprenorphine application is negligible. Following transdermal application, buprenorphine is eliminated via hepatic metabolism, with subsequent biliary excretion and renal excretion of soluble metabolites. Hepatic metabolism, through CYP3A4 and UGT1A1/1A3 enzymes, results in two primary metabolites, norbuprenorphine and buprenorphine 3-O-glucuronide, respectively. Norbuprenorphine is glucuronidated before elimination. Buprenorphine is also eliminated in the faeces. In a study in post-operative patients, the total elimination of buprenorphine was shown to be approximately 551/h.Norbuprenorphine is the only known active metabolite of buprenorphine.
Effect of buprenorphine on the pharmacokinetics of other active substances:Based on in vitro studies in human microsomes and hepatocytes, buprenorphine does not have the potential to inhibit metabolism catalysed by the CYP450 enzymes CYP1A2, CYP2A6 and CYP3A4 at concentrations obtained with use of buprenorphine 20μg/h transdermal patch. The effect on metabolism catalysed by CYP2C8, CYP2C9 and CYP2C19 has not been studied.
Adhesive matrix (containing buprenorphine):povidone K90levulinic acidoleyl oleatePoly[acrylic acid-co-butylacrylate-co-(2-ethylhexyl)acrylate-co-vinylacetate] (5:15:75:5)
Adhesive matrix (without buprenorphine):Poly[(2-ethylhexyl)acrylate-co-glycidylmethacrylat-co-(2-hydroxyethyl)acrylate-co-vinylacetate] (68:27:5:0,15)Separating foil between adhesive matrices with and without buprenorphine: PET film Backing web: polyesterRelease liner: PET film (to be removed before applying the patch)Blue printing ink
Type of container:Each child-proof sachet is made of a composite layer material consisting of Paper/ PET/ PE/ Aluminium/ Surlyn. One sachet contains one transdermal patch.
Pack sizes:Packs containing 4 individually sealed transdermal patches.Not all pack sizes may be marketed.
Disposal after use:When changing the patch, the used patch should be removed, the adhesive layer folded inwards on itself, and the patch disposed of safely and out of sight and reach of children.
6 Riverview Road, Beverley, Hull, HU17 0LD
+44 (0)1482 860228
+44 (0)1748 828873
+44 (0)1482 389858